PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF BTRX-246040 IN PARKINSON'S DISEASE SUBJECTS WITH MOTOR FLUCTUATIONS ( PROTOCOL NEP-PD-201)
Clinical Trial Grant
Administered By
Neurology, Movement Disorders
Awarded By
BlackThorn Therapeutics
Start Date
September 14, 2018
End Date
November 27, 2019
Administered By
Neurology, Movement Disorders
Awarded By
BlackThorn Therapeutics
Start Date
September 14, 2018
End Date
November 27, 2019